Jaguar Health targets mid-2027 MVID NDA filing with possible end-2027 U.S. approval, backed by up to 48% parenteral support reductions (NASDAQ:JAGX)
· seekingalpha.com
Jaguar Health (JAGX) Q2 2026 earnings call: crofelemer rare-disease GI update, ESPGHAN data, BTD/NDA timeline and financials—read now.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...